Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Shareholder Approval of Business Combination

<< Previous

Bullboard Posts

Next >>

Comment by beenthereon Aug 05, 2021 9:33pm

130 Views

Post# 33661796

RE:Shareholder Approval of Business Combination

No surprise there but ....

I have read twice now that ...."under the symbol MSCL during the week of August 9, 2021. "

WHAT gives with that??????

Don't give us the "week" give us the " day"!!

WHAT day is MSCL going to start to trade??

WE as investors deserve to know IN ADVANCE what day we are going to start to trade!

What the h*ll!